AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Oramed Pharmaceuticals Inc. Director's Dealing 2024

Nov 8, 2024

6965_dirs_2024-11-08_a88ad8c6-8f6b-4c76-96c3-2f567d663e90.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2024-11-07

Reporting Person: KIDRON NADAV (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-11-07	Common Stock	A	45000	—	Acquired	1826098	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	126000	Indirect

Footnotes

F1: Represents Restricted Stock Units ("RSUs") that will vest on November 7, 2024. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.